Founders in biotech Podcast
1) Marco De Vivo on Neuroscience Drug Discovery
Marco De Vivo, is the head of the Molecular Modeling and Drug Discovery lab at the Italian Institute of Technology. He is also the Associate Director of the IIT, responsible for Computational Sciences...Show More
2) Maria Soloveychik on synthetic biology for discovery of protein interaction modulators
Maria Soloveychik is the co-founder and CEO of SyntheX, a therapeutics company accelerating drug discovery through synthetic biology. SyntheX, founded in 2016 and headquartered in San Francisco, advan...Show More
3) Christoph Lengauer on building visionary biotech companies
Christoph Lengauer has contributed to the development of 10 FDA-approved cancer medicines. Christoph is Chief Scientific Officer and a co-founder of Curie.Bio, where he and his team co-pilot seed-stag...Show More
4) Deep dive into business development in biotech with James Lee
Business development is an essential process for biotech companies to build relationships with partners and create value from the deal structures that are based on science. We are taking a deep dive w...Show More
5) James Lee on the vital role of business development for biotech companies
James Lee received his B.S and M.S. in Structural Biology from Seoul National University, he held various roles in research, research planning, and business development at LG Chem. In year 2000, James...Show More
6) Yaniv Erlich on building a scalable platform to discover next-gen RNA therapeutics.
Prof. Yaniv Erlich received his bachelor’s degree from Tel-Aviv University, Israel in 2006 and a PhD from the Watson School of Biological Sciences at Cold Spring Harbor Laboratory in 2010. Yaniv Erlic...Show More
Yaniv Erlich on building a scalable platform to discover next-gen RNA therapeutics.
1:01:18 | Oct 4th, 2023
7) Kiyoshi Takayama on targeting challenging GPCRs using monoclonal antibodies
Kiyoshi Takayama has received a Ph.D. in pharmaceutical science from the University of Tokyo. After his PhD he worked for more than 12 years as a research scientist at Taisho Pharmaceutical, Japan, wh...Show More
Kiyoshi Takayama on targeting challenging GPCRs using monoclonal antibodies
53:26 | Aug 9th, 2023
8) David Younger on how synthetic biology helps to identify molecular glues
David Younger is a bioengineer and started his biotech journey directly after his PhD. David’s scientific research was focused on the application of synthetic biology techniques for high-throughput sc...Show More
9) Elaine Hamm on overcoming the “shiny object syndrome” in biotech
The path from the lab bench to market in biotech has many hurdles and lots of opportunities. Sometimes too many. Elaine Hamm has experienced all stages of bringing innovation from academia to a succes...Show More
10) Deep dive into targeted protein degradation and PROTACs with Alession Ciullli
Targeted protein degradation, TPD, is a new and disruptive therapeutic approach for development of medicines. TPD opened doors to develop small molecules to drug the ‘undruggable’. Instead of bl...Show More
Deep dive into targeted protein degradation and PROTACs with Alession Ciullli
22:35 | Sep 8th, 2022